FDA Accepts Eluminex Biosciences' IND Application for Trispecific Fusion Antibody for DME

Eluminex Biosciences announced the acceptance of its EB-105 IND application to the FDA. EB-105 is a novel trispecific fusion antibody targeting VEGF-A (and isomers), VEGF-B, placental growth factor (PlGF), angiopoetin-2 (Ang-2), and interleukin-6 receptor (IL-6R) for the treatment of DME. 

“Elevated levels of IL-6 in the vitreous have been well-documented in patients with DME, even with ongoing anti-VEGF treatments. Furthermore, IL-6 is over-expressed and contributes to inflammation and vascular permeability in other retinal disorders including neovascular (wet) age-related macular degeneration, retinal vein occlusion, and uveitic macular edema. High levels of IL-6 may likely be the reason for persistent refractory edema in DME patients being treated with current agents such as aflibercept and faricimab,” Quan Dong Nguyen, MD, MSc, FARVO, FASRS, Professor of Ophthalmology (Retina and Uveitis) at the Byers Eye Institute, and Professor of Medicine and Professor of Pediatrics at Stanford University School of Medicine, said in a company news release. “The ability to inhibit several biological pathways simultaneously with a single agent offers compelling potential for further incremental benefits in patients with retinal diseases."

Details of EB-105 mechanism of action and preclinical science will be presented at the following venues:

• Oral presentation. EB-105: A Novel Trispecific Antibody for DME, will be presented by Charles P. Semba, MD, Chief Medical Officer (CMO) of Eluminex, at the OIS Meeting, May 4, 2024, Session on Diabetic Macular Edema and Diabetic Retinopathy, 2:15 – 3:30 PM, Four Seasons Hotel, Seattle, WA.
• Poster presentation. EB-105: A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (Poster B0123, Abstract 4027224), will be presented by Weiyong Shen, MD, PhD, Senior Vice President, Preclinical Development of Eluminex, at the ARVO Meeting, May 9, 2024, 11:45 AM to 1:30 PM, Exhibit Hall – Seattle Convention Center, Seattle, WA.
• Oral presentation. EB-105: When Three is Not a Crowd – A Novel Trispecific Antibody for Retinal Disease, will be presented by Charles P. Semba, MD, CMO of Eluminex, at the Clinical Trials at the Summit Meeting, June 8, 2024, Pendry Park City Hotel, Park City, UT.

Eluminex is actively seeking strategic alliances and investment partnerships to help support the emerging programs in retinal disease and dermal facial aesthetics.